Figure 1
Nonmyeloablative BM transplantation in Hmox1−/− mice improved blood chemistries and led to resolution of anemia. (A) Scheme of the BM transplantation experiment used for subsequent data collection. (B) BM engraftment dynamics are represented as a percentage of CD45.2-positive leukocytes in peripheral blood estimated by fluorescence-activated cell sorter analysis. Changes over weeks are plotted for each individual mouse. (C) Hmox1−/− mice had elevated serum ALP and LDH levels. The blood chemistries returned to normal in BM transplanted recipients. (D) Indicators of microcytic anemia mean cell volume and hematocrit improved in BM-transplanted Hmox1−/− mice. (C-D) Average values for the terminal time, 21 weeks, are shown for each experimental group; error bars represent the standard deviation (N = 5). TMS water, drinking water supplemented with trimethoprim (300 μg/ml) and sulfamethoxazole (60 μg/ml).

Nonmyeloablative BM transplantation in Hmox1−/− mice improved blood chemistries and led to resolution of anemia. (A) Scheme of the BM transplantation experiment used for subsequent data collection. (B) BM engraftment dynamics are represented as a percentage of CD45.2-positive leukocytes in peripheral blood estimated by fluorescence-activated cell sorter analysis. Changes over weeks are plotted for each individual mouse. (C) Hmox1−/− mice had elevated serum ALP and LDH levels. The blood chemistries returned to normal in BM transplanted recipients. (D) Indicators of microcytic anemia mean cell volume and hematocrit improved in BM-transplanted Hmox1−/− mice. (C-D) Average values for the terminal time, 21 weeks, are shown for each experimental group; error bars represent the standard deviation (N = 5). TMS water, drinking water supplemented with trimethoprim (300 μg/ml) and sulfamethoxazole (60 μg/ml).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal